You Asked: How Worrisome is the Boxed Warning for the New Postpartum Depression Medication?
The package insert advises patients to avoid driving and other potentially hazardous activities after taking zuranolone.
The package insert advises patients to avoid driving and other potentially hazardous activities after taking zuranolone.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on December 14, 2023.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms.
The PLLR helps to put the potential effects of the drug into perspective with the goal of providing a more individualized risk-benefit analysis.
The FDA will review zuranolone for the treatment of depression in the first half of 2022.
Last week, I met with a woman who was planning pregnancy. She had a long history of generalized anxiety disorder and panic disorder and had done very well over the past 10 years on [...]